$LYB

LyondellBasell Industries (LYB) Reports Stronger Results, Is The Stock Still Cheap?

Simply Wall St reports LyondellBasell (NYSE:LYB) posted Q2 2026 sales of $9,177 million and net income of $558 million, both above the prior year period. The article notes LYB shares at $62.40, up 40.57% YTD, and cites a fair value estimate of $69.53 versus the last close. It highlights risks from weak petrochemical pricing and potential delays to MoReTec-2 and Flex-2.

Original reporting
Published Aug 14, 2026, 8:58 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 14, 2026, 11:54 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
LyondellBasell Industries (LYB) Reports Stronger Results, Is The Stock Still Cheap? — source image
Decision brief

The 30-second read

$LYBBullishLow
01

Why it matters

The earnings beat versus the prior year is the only concrete new datapoint, while the rest is valuation-model discussion and risk framing around pricing and project timing.

02

Market read

Traders get a quick earnings datapoint plus a valuation gap narrative, but no new guidance or operational update is provided.

03

What to watch

No details are provided on segment margins, cash flow, guidance, or the actual status/timing of MoReTec-2 and Flex-2, which are key to validating the valuation gap.

Relevance 4/10Novelty 4/10Timing: after-hours/early pre-market read-through of Q2 2026 results (published 2026-08-14 08:58 UTC)

Background

Simply Wall St discusses LYB’s Q2 2026 results and overlays a fair-value narrative versus the current share price.

Company-level read

Ticker impact

$LYBBullishMedium confidence
Context

LYB reported Q2 2026 sales of $9,177 million and net income of $558 million, both higher than the prior-year period.

Expected impact

Near-term bias modestly positive on earnings momentum, but upside may be capped if margin recovery assumptions or project timelines disappoint.

Evidence & confidence

The text provides concrete earnings datapoints and a fair-value narrative ($69.53 vs $62.40), yet it does not add new guidance, margin figures, or project update specifics beyond risk framing.

Market effects

A stronger print at a major chemicals/polymers producer can support sentiment for packaging, infrastructure, and automotive-linked polymer demand.

No specific regional demand or policy drivers are disclosed in the text.

The article ties demand to global urbanization and emerging-market consumption, but provides no new macro datapoints.

Counterpoint

The “undervalued” framing may be largely model-driven, while the article itself highlights that weak petrochemical pricing or project delays could negate the earnings rebound.

Key entities

  • LyondellBasell Industries

    Subject of the article, reporting Q2 2026 sales and net income higher than the prior-year period.

Related articles

$SHELMedAI 8/10

Business Watch: DOE gives out money for batteries; Genentech licenses a GLP-1 alternative

Shell is receiving bids for its US petrochemical business, potentially worth $8 billion, from rivals like LyondellBasell and ExxonMobil, as well as private equity firms. The sale may include Shell's ethylene and polyethylene complex in Pennsylvania and other sites. LyondellBasell has a history of acquiring new plants at lower prices, while ExxonMobil is already in related businesses. Kuwait Petroleum may be interested in Shell's ethylene oxide derivatives.

$XOMHighAI 9/10

Exxon and LyondellBasell Eye Shell’s US Chemicals Portfolio – FT

Exxon Mobil (XOM) and LyondellBasell (LYB) are among potential bidders for Shell's (SHEL) US chemicals assets, valued at up to $8B. Other interested parties include Apollo and Kuwait Petroleum Corporation. The portfolio includes four facilities, with Shell seeking to divest weaker-performing operations. Shell is also reviewing European chemicals assets for potential sales.

$SHELMedAI 8/10

Shell’s Chemicals Exit Attracts XOM and LYB: Capital Discipline or Missed Opportunity?

Shell (NYSE:SHEL) may sell its U.S. chemicals business for up to $8B, with ExxonMobil (XOM) and LyondellBasell (LYB) among potential buyers. The sale aligns with CEO Wael Sawan's strategy to focus on higher-return sectors like oil, gas, and LNG. Shell's Q2 2026 net profit was $9.84B, with net debt at $41.8B. The move could reinforce Shell's focus but risks undervaluing long-term chemicals demand.